Clinical Trials Logo

Clinical Trial Summary

The hemolytic disease of newborns (HDN) is one of the most significant risk factors for hyperbilirubinemia. Studies have shown that end-tidal carbon monoxide-corrected (ETCOc) correlated with the rate of bilirubin production in the body and thus can be a good surrogate to quantify hemolysis and identifying the high-risk infants. However, there is insufficient clinical evidence regarding the early prediction of hemolytic hyperbilirubinemia using ETCOc. This study hypothesizes that early postnatal ETCOc levels are significantly associated with the risk of hemolytic hyperbilirubinemia requiring treatments within 14 days after birth, and early postnatal ETCOc can be a good indicator for early prediction of hemolysis. In addition, the investigators aim to investigate the relationship between the characteristics of treatments for hyperbilirubinemia and ETCOc.


Clinical Trial Description

Study design: this study is a multi-center, prospective observational cohort study on neonatal jaundice. Eligible participants will be enrolled in the well-baby nursery and neonatal intensive care units (NICU). Transcutaneous bilirubin and/or total serum bilirubin (TCB/TSB) will be measured as per clinical practice and simultaneous ETCOc (within time intervals ≤3 hours) will be monitored until (1) the newborn is discharged with the mother, or (2) until 72 hours after birth or (3) requiring the treatments for hyperbilirubinemia (phototherapy and/or exchange transfusion) (whichever comes first). For infants who do not require treatments for hyperbilirubinemia (phototherapy and/or exchange transfusion) during the stay in well-baby nursery or in the NICU within 72 hours after birth, they will be followed up via telephone or outpatient clinic visits during the first 14 days of life (DOL). The primary outcome is the first occurrence of hemolytic hyperbilirubinemia requiring treatments within DOL14. For participants who have the primary outcome occurred within DOL14, follow-up calls/visits will continue until DOL28 to record the readmissions due to hyperbilirubinemia within 28 DOL . The secondary outcomes are 1) the incidence of hemolytic diseases of newborns; 2) characteristics of treatment for hemolytic hyperbilirubinemia: postnatal age when requiring the treatment, levels of TCB/TSB/ETCOc during hospitalization, length of stay, length of phototherapy, courses of phototherapy, exchange of transfusion, the use of intravenous immunoglobulin; 3) characteristics of readmission for hyperbilirubinemia in 28 DOL: readmission for hyperbilirubinemia in 28 DOL, postnatal age when readmitted, TCB/TSB levels when readmitted Exposures and measurements: 1. Early postnatal (≤72 hours) ETCOc levels 2. ETCOc levels within 14 days after birth 3. ETCOc levels before each phototherapy and/or exchange transfusion treatment 4. ETCOc levels when stopping phototherapy and/or exchange transfusion treatment Covariates and characteristics: covariates will be collected including maternal and prenatal history (e.g., mother's blood type [ABO and Rh type], G6PD deficiency status, etc.), family history (e.g., history of hemolytic diseases in the previous newborn, history of NHB treatment in the previous newborn, etc.). Clinical characteristics include demographic characteristics (e.g., gestational age, birth weight), infant's blood type (ABO and Rh type), the status of G6PD deficiency,ABO incompatibility and hemolysis, feeding history and other risk factors (e.g., early discharge after birth, excessive weight loss and the presence of hematoma) as well as data related to the primary and secondary outcomes. For analysis, this study will examine the association between early postnatal ETCOc and the incidence of hemolytic hyperbilirubinemia, and the relation of ETCOc levels with the characteristics of treatments for hyperbilirubinemia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06341582
Study type Observational [Patient Registry]
Source Guangzhou Women and Children's Medical Center
Contact Ge Yang, M.D.
Phone (86)020-38076329
Email geyang99@outlook.com
Status Recruiting
Phase
Start date December 11, 2023
Completion date November 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04365998 - BUBOLight®, a New Phototherapy Device for the Treatment of the Newborn's Jaundice N/A
Completed NCT02222805 - Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment N/A
Completed NCT01622699 - Implementation of a Transcutaneous Bilirubinometer N/A
Completed NCT00692224 - Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial Phase 1/Phase 2
Not yet recruiting NCT06080971 - Persistent Neonatal Jaundice on Neonates and Childern
Recruiting NCT06075290 - the Difference of Follow-up Methods of Neonatal Jaundice
Recruiting NCT05955144 - Clinical Validation of the Screening Tool Picterus JP Using Different Smartphones N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Completed NCT03306004 - Neonatal Jaundice: Knowledge, Attitudes and Practices of Mothers and Medical Trainees and Providers in and Around Ogbomosho N/A
Completed NCT02774434 - Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age N/A
Terminated NCT05365399 - Evaluation of a Smartphone-based Screening Tool for Neonatal Jaundice in a Ugandan Population N/A
Recruiting NCT03933423 - Home Based Phototherapy for Neonatal Jaundice N/A
Recruiting NCT06087874 - Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice Phase 2
Recruiting NCT06399146 - Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana N/A
Recruiting NCT03183986 - Comparison of the Efficacy of Phototherapy Using Blue LED's With Wavelength 478 vs. 459 nm. N/A
Withdrawn NCT00917007 - Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
Completed NCT06227624 - Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia Phase 3
Completed NCT04418180 - Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants N/A
Completed NCT04433923 - Aluminium Foil as an Adjuvant to Phototherapy for Pathological Unconjugated Hyperbilirubinaemia in Full Term Infants N/A
Completed NCT06386731 - Continuous Versus Intermittent Phototherapy in Treatment of Neonatal Jaundice N/A